- Home
- GLMD vs ARTL Comparison
GLMD vs ARTL Comparison
Compare GLMD & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- ARTL
- Stock Information
- Founded
- GLMD 2000
- ARTL 2011
- Country
- GLMD Israel
- ARTL United States
- Employees
- GLMD N/A
- ARTL N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- ARTL Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- ARTL Health Care
- Exchange
- GLMD Nasdaq
- ARTL Nasdaq
- Market Cap
- GLMD 3.0M
- ARTL 3.1M
- IPO Year
- GLMD 2014
- ARTL N/A
- Fundamental
- Price
- GLMD $1.57
- ARTL $1.04
- Analyst Decision
- GLMD Hold
- ARTL Strong Buy
- Analyst Count
- GLMD 1
- ARTL 2
- Target Price
- GLMD N/A
- ARTL $5.50
- AVG Volume (30 Days)
- GLMD 105.5K
- ARTL 1.2M
- Earning Date
- GLMD 05-29-2025
- ARTL 05-12-2025
- Dividend Yield
- GLMD N/A
- ARTL N/A
- EPS Growth
- GLMD N/A
- ARTL N/A
- EPS
- GLMD N/A
- ARTL N/A
- Revenue
- GLMD N/A
- ARTL N/A
- Revenue This Year
- GLMD N/A
- ARTL N/A
- Revenue Next Year
- GLMD N/A
- ARTL N/A
- P/E Ratio
- GLMD N/A
- ARTL N/A
- Revenue Growth
- GLMD N/A
- ARTL N/A
- 52 Week Low
- GLMD $1.21
- ARTL $0.82
- 52 Week High
- GLMD $23.80
- ARTL $1.59
- Technical
- Relative Strength Index (RSI)
- GLMD 48.70
- ARTL 54.43
- Support Level
- GLMD $1.30
- ARTL $0.88
- Resistance Level
- GLMD $1.67
- ARTL $1.16
- Average True Range (ATR)
- GLMD 0.14
- ARTL 0.14
- MACD
- GLMD 0.06
- ARTL 0.02
- Stochastic Oscillator
- GLMD 78.77
- ARTL 37.93
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.